Simon Fraser - Smith Nephew President - Advanced Wound Management
SNNUF Stock | USD 12.31 0.40 3.15% |
President
Mr. Simon Fraser is President Advanced Wound Management of the Company. He Joined Smith Nephew in January 2019 with commercial leadership responsibility for Advanced Wound Management in the US and global upstream marketing for the Advanced Wound Management Franchise. As part of his executive responsibilities Simon will also provide leadership for Healthcare Systems. Simon is based in Fort Worth, US. Skills and Experience Simon brings to this role more than 25 years of experience across medical devices, pharmaceuticals and diagnostics, including wound management. Importantly, he is a purposedriven and accomplished business leader who has successfully managed large, global commercial organisations with full PL responsibility while growing business and earning market share. Prior to joining Smith Nephew Simon was Group Vice President of DentsplySironas Dental Implant Global Business Unit. Prior to this Simon was Vice President, US Commercial Infectious Diseases including corporate accounts at Abbott Laboratories. Simon joined Abbott following the acquisition of Alere where he had three successful years as the President of Latin America. Prior to these roles, Simon had a 15year career with Johnson Johnson, where he held increasingly senior commercial roles spanning surgical devices, wound management, implants and pharmaceuticals including both global strategic marketing and PL responsibilities. since 2019.
Age | 50 |
Tenure | 5 years |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Jonathan Monson | Boston Scientific Corp | N/A | |
Kathryn Fink | Stryker | 48 | |
Thomas Frinzi | Abbott Laboratories | 60 | |
Hubert Allen | Abbott Laboratories | 58 | |
Catherine Szyman | Edwards Lifesciences Corp | 54 | |
Sian Roberts | Align Technology | N/A | |
Lonny Carpenter | Stryker | 55 | |
Chad Phipps | Zimmer Biomet Holdings | 52 | |
David Pierce | Boston Scientific Corp | 57 | |
Joseph Cucolo | Zimmer Biomet Holdings | 55 | |
Glenn Boehnlein | Stryker | 62 | |
Karen Prange | Boston Scientific Corp | 52 | |
Robert Marshall | Zimmer Biomet Holdings | N/A | |
Fink | Stryker | 47 | |
Bradley Lerman | Medtronic PLC | 63 | |
William Berry | Stryker | 58 | |
Heather Mason | Abbott Laboratories | 56 | |
Michael Phalen | Boston Scientific Corp | 56 | |
Lanny Roper | DexCom Inc | 50 | |
Scott Ullem | Edwards Lifesciences Corp | 57 | |
Julie Tay | Align Technology | 51 |
Management Performance
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 |
Smith Nephew Plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director | ||
Michael Friedman, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Director | ||
Deepak Nath, CEO Director | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Director | ||
AnneFrancoise Nesmes, CFO Director | ||
Helen Barraclough, Company Counsel | ||
Rodrigo Bianchi, President IRAMEA | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, Sports Orthopaedics | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Non-Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Director | ||
Simon Fraser, President - Advanced Wound Management | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, CFO, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, VP Communications | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Glenn Warner, President - Advanced Wound Management | ||
Robin Freestone, Non-Executive Director | ||
Paul Connolly, Pres Operations | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Director | ||
Mark Gladwell, President - Global Operations | ||
Andrew Swift, VP Relations | ||
Vasant Padmanabhan, President - Research & Development | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Joseph Papa, Non-Executive Independent Director | ||
Ingeborg Oie, VP, Investor Relations | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President Europe and Canada | ||
Ian Barlow, Non-Executive Independent Director | ||
Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 | |||
Profit Margin | 0.1 % | |||
Operating Margin | 0.14 % | |||
Current Valuation | 14.08 B | |||
Shares Outstanding | 873.35 M | |||
Shares Owned By Insiders | 0.17 % | |||
Shares Owned By Institutions | 52.60 % | |||
Price To Earning | 23.41 X | |||
Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |